Physician profile
Robert Levitt
NPI 1225054398
$3,287.78
in general payments reported to CMS, 2019-2025
26 companies · $247 in 2025
The $247 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,496 · 2020: $342 · 2021: $84.89 · 2022: $605 · 2023: $125 · 2024: $388 · 2025: $247.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $760.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $759.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $488.21 | 2019-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $283.15 | 2021-2022 | |
| Janssen Scientific Affairs, LLC | $237.76 | 2019-2020 | |
| Optinose US, INC. | $234.87 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $227.70 | 2019-2020 | |
| Pfizer INC. | $215.95 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $179.41 | 2019 | |
| Janssen Biotech, INC. | $157.96 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $147.87 | 2024 | Strensiq |
| Insmed, INC. | $125.17 | 2022 | |
| Novo Nordisk INC | $125.00 | 2023 | Wegovy |
| Astrazeneca Pharmaceuticals LP | $125.00 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $120.17 | 2019-2020 | |
| Genzyme Corporation | $115.67 | 2025 | |
| Amgen INC. | $105.27 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $101.93 | 2019 | |
| Ucb, INC. | $98.66 | 2019 | |
| Intercept Pharmaceuticals, INC. | $44.32 | 2019 | |
| Ferring Pharmaceuticals INC. | $30.36 | 2019 | |
| Allergan, INC. | $29.24 | 2019 | |
| Intra-Sana Laboratories | $20.61 | 2025 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
| Shionogi INC | $17.37 | 2019 | |
| Daiichi Sankyo INC. | $15.55 | 2019 | |
| Ironwood Pharmaceuticals, INC | $14.61 | 2019 | |
| Vivus LLC | $14.51 | 2019 | |
| Alnylam Pharmaceuticals INC. | $11.46 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Levitt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.